InSightec Treats First Prostate Cancer Patients in Clinical Trials

ExAblate(R) MR Guided Focused Ultrasound System is Being Used for the First Time for Non-invasive Treatment of Prostate Cancer

TIRAT CARMEL, Israel, August 31, 2010 - InSightec Ltd., the global leader in MR guided focused ultrasound
technology and the only company to receive FDA approval for its ExAblate(R)
system for treating uterine fibroids, announced today that its ExAblate(R)
system has been used for the first time for the treatment of prostate cancer
patients. Seven patients with localized low-risk prostate cancer were treated
worldwide so far. The patients were treated at two leading medical centers:
the N.N. Petrov Research Institute of Oncology in Saint Petersburg, Russia,
and at the National Cancer Centre at the Singapore General Hospital,
Singapore.

Prostate cancer is one of the most commonly diagnosed cancers among men.
According to the American Cancer Society 217,730 new cases of prostate cancer
will be diagnosed in the US in 2010; and 900,000 new cases diagnosed
globally, according to the World Health Organization. The annual spending in
G7 countries (US, UK, France, Italy, Germany, Spain and Japan) is estimated
at 15 Billion Dollars. Treatment options include prostatectomy (surgical
removal of the prostate gland), radiation therapy, brachytherapy
(implantation of radioactive seeds), and cryotherapy. Ultrasound guided high
intensity focused ultrasound (HIFU) has also been used, outside the US, to
treat prostate cancer.

"Unfortunately current treatment alternatives are accompanied by
relatively high levels of adverse events which significantly impact the
quality of life of prostate cancer patients. The most common are incontinence
and impotence", says Dr. Kobi Vortman, President and CEO of InSightec. "Due
to the introduction of PSA screening tests, prostate cancer is diagnosed at
an earlier age thereby increasing the necessity for a treatment option that
minimizes adverse events. The ExAblate prostate system has been designed to
provide effective treatments while minimizing the debilitating side-effects
caused by damage to functional areas of the prostate and neurovascular
bundles, thus the system is expected to enable patients to return to normal
life within a day or two while maintaining their quality of life."

The ExAblate system, which has been in clinical use for the treatment of
uterine fibroids globally and bone metastases outside of the US, is an Image
Guided, Non-invasive, Robotic Acoustic Surgery system integrating real time
magnetic resonance imaging to visualize the tumor, surrounding tissue and the
energy delivery path together with high intensity focused ultrasound beam
which is delivered with millimeter precision to destroy the cancerous tumor
without damaging surrounding tissue, which is the cause of most
complications. The use of real-time 3D MR thermometry provides accurate
closed-loop monitoring of the treatment outcome and ability to adjust the
treatment according to specific patient physiology, in real time.

"Current treatment options for low risk prostate cancer patients have
shown limited success in preserving potency and continence functions. We
believe that with the ExAblate non-invasive procedure we stand a better
chance of minimizing life time morbidity without compromising life
expectancy", says Associate Professor Christopher Cheng, Head & Senior
Consultant, Department of Urology Singapore General Hospital, Singapore.

In the prostate cancer therapy application the major expected benefits of
the ExAblate treatment are:

    - Low complication rate
    - Non-invasive treatment, patients back to their life within a day
      or two
    - Non-ionized radiation
    - Single session therapy
    - Real time MR thermometry monitoring that is used to control
      treatment outcome during treatment

"We are very pleased to have been the first facility to adopt the
ExAblate system for Phase 1 prostate cancer clinical trials." said principle
investigator Professor S.V. Kanaev, Chairman of Radiation Oncology, N.N
Petrov Research Institute of Oncology. "We have had excellent results with
ExAblate in treating patients suffering from bone metastases and we believe
it has tremendous potential in treating prostate cancer patients with a low
complication rate. We and our patients have been very pleased with the
results achieved to date."

InSightec will shortly be expanding the prostate clinical trials to
additional leading sites globally.

About InSightec

InSightec Ltd. is a privately-held company owned by Elbit Imaging,
General Electric, MediTech Advisors, LLC and employees. It was founded in
1999 to develop the breakthrough MR guided Focused Ultrasound technology and
transform it into the next generation operating room. Headquartered near
Haifa, Israel, the company has over 160 employees and has invested more than
$130 million in research, development, and clinical investigations. Its U.S.
headquarters are located in Dallas, Texas. For more information, please go
to: www.insightec.com/

About ExAblate(R)

ExAblate is an Image Guided, Non-invasive, Robotic Acoustic Surgery
system. The ExAblate system is the first to use the MR guided focused
ultrasound technology that combines MRI - to visualize the body anatomy, plan
the treatment and monitor treatment outcome in real time - and high intensity
focused ultrasound to thermally ablate tumors inside the body non-invasively.
MR thermometry, provided uniquely by the system, allows the physician to
control and adjust the treatment in real time to ensure that the targeted
tumor is treated and surrounding non targeted tissue is spared. The ExAblate
system was approved by the U.S. Food and Drug Administration in 2004 as a
treatment for symptomatic uterine fibroids. Over 6,000 women have been
treated worldwide to date with excellent results. ExAblate(R) 2000 received
the European CE Mark for pain palliation of bone metastases in June 2007 and
for Adenomyosis in June 2010.

    Media Contact:

    For further information please contact:
    Dr. Jane Brearley
    Waggener Edstrom Worldwide
    Tower House
    10 Southampton Street
    Covent Garden
    London
    WC2E 7HA
    Email: jbrearley@waggeneredstrom.com
    Phone: +44-(0)20-7632-3800

Media Contact: For further information please contact: Dr. Jane Brearley, Waggener Edstrom Worldwide, Tower House, 10 Southampton Street, Covent Garden, London, WC2E 7HA, Email: jbrearley at waggeneredstrom.com, Phone: +44-(0)20-7632-3800